Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
A previous October 2020 report concluded that longer-term safety and efficacy were needed to update health-benefit price benchmarks. In August 2020, the agency had rejected an approval application, suggesting the company complete its Phase III Gener8-1 study and include two-year follow-up safety and efficacy data. million price tag.
111 
Let's personalize your content